



Press Release

Paris, 02 December 2014

KURMA Partners invests in Xeltis, a leading regenerative medicine company with first product targeting orphan and severe cardiac malformations

Kurma Partners, a key European player in the financing of Innovation in Healthcare, announces its investment in Xeltis, a private Swiss/Dutch regenerative medicine company developing a new generation of pulmonary valves and vascular grafts. Xeltis has raised 27 million Euros in a Series B financing, co-led by Kurma Partners (Kurma), France and Life Sciences Partners (LSP), the Netherlands (LSP) alongside VI Partners, Switzerland, and current shareholders of Xeltis.

Xeltis' proprietary technology, based on Nobel prize-winning science, is designed to induce the body's natural healing response from the inside, leading to spontaneous growth of new valves and vessels within the body, once the fully synthetic matrice is implanted. The matrices are intended to biodegrade as natural tissue grows, leaving no foreign material behind. The company's first product, a pulmonary valve, addresses orphan pediatric indication of severe congenital malformations of the heart.

"We have been impressed by the broad potential of Xeltis' breakthrough technology and by the team's achievements in turning this innovation into game-changing products in cardiology and surgery" said Vanessa Malier, partner at Kurma, who joins the Board of Directors of Xeltis. "Xeltis' first product will target rare cardiac malformations affecting children. This investment fits perfectly with our fund strategy".

A propos de KURMA Partners - www.kurmapartners.com

KURMA Partners is a key European player in the financing of Innovation in Healthcare and Biotechnology, from pre-seed to growth capital, notably through Kurma Biofund I and II, and strategic partnerships with prestigious European research and medical institutions. Kurma Biofund II is the first Venture Capital fund dedicated to financing innovation in the rare diseases space.



A propos de Xeltis

For more information, visit <http://www.xeltis.com>

<http://www.xeltis.com/wp-content/uploads/Xeltis-Series-B-release-EN.pdf>

Press contacts

NewCap. - Nicolas Merigeau : +33(0)1 44 71 94 98 - nmerigeau@newcap.fr